Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)

This study has been completed.

First Received: July 4, 2006 Last Updated: March 26, 2009 History of Changes

Sponsored by:	Sanofi-Aventis
Information provided by:	Sanofi-Aventis
ClinicalTrials.gov Identifier:	NCT00349180

Purpose

This study is performed to confirm the optimal dose for THR (total hip replacement).

Condition	Intervention	Phase
Arthroplasty, Replacement, Hip	Drug: Enoxaparin sodium	Phase III

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double-Blind, Dose Comparison, Parallel Assignment, Efficacy Study
Official Title:	Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium（RP54563）20mg qd and 20mg Bid for 14 Days in Patients With Total Hip Replacement

Resource links provided by NLM:

Drug Information available for: Enoxaparin Sodium

Further study details as provided by Sanofi-Aventis:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	156
Study Start Date:	June 2006

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00349180

Locations

Sponsors and Collaborators

Sanofi-Aventis

Investigators

Study Director:

Yoshihiro IKEDA

Sanofi-Aventis

More Information

Additional Information:

Related Info This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	EFC6770
Study First Received:	July 4, 2006
Last Updated:	March 26, 2009
ClinicalTrials.gov Identifier:	NCT00349180 History of Changes
Health Authority:	Japan: Ministry of Health, Labor and Welfare

Keywords provided by Sanofi-Aventis:

Total Hip Replacement
Enoxaparin

Study placed in the following topic categories:

Fibrin Modulating Agents
Anticoagulants
Fibrinolytic Agents
Cardiovascular Agents
Enoxaparin

Additional relevant MeSH terms:

Fibrin Modulating Agents
Anticoagulants
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Hematologic Agents

Fibrinolytic Agents
Cardiovascular Agents
Pharmacologic Actions
Enoxaparin

ClinicalTrials.gov processed this record on September 11, 2009